1. Home
  2. ACET vs BW Comparison

ACET vs BW Comparison

Compare ACET & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • BW
  • Stock Information
  • Founded
  • ACET 1947
  • BW 1867
  • Country
  • ACET United States
  • BW United States
  • Employees
  • ACET N/A
  • BW N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • BW Building Products
  • Sector
  • ACET Health Care
  • BW Industrials
  • Exchange
  • ACET Nasdaq
  • BW Nasdaq
  • Market Cap
  • ACET 111.9M
  • BW 119.1M
  • IPO Year
  • ACET N/A
  • BW N/A
  • Fundamental
  • Price
  • ACET $0.58
  • BW $6.26
  • Analyst Decision
  • ACET Buy
  • BW Buy
  • Analyst Count
  • ACET 4
  • BW 2
  • Target Price
  • ACET $8.50
  • BW $5.50
  • AVG Volume (30 Days)
  • ACET 1.8M
  • BW 6.7M
  • Earning Date
  • ACET 11-05-2025
  • BW 11-04-2025
  • Dividend Yield
  • ACET N/A
  • BW N/A
  • EPS Growth
  • ACET N/A
  • BW N/A
  • EPS
  • ACET N/A
  • BW N/A
  • Revenue
  • ACET N/A
  • BW $721,285,000.00
  • Revenue This Year
  • ACET N/A
  • BW N/A
  • Revenue Next Year
  • ACET N/A
  • BW $8.02
  • P/E Ratio
  • ACET N/A
  • BW N/A
  • Revenue Growth
  • ACET N/A
  • BW 80.30
  • 52 Week Low
  • ACET $0.45
  • BW $0.22
  • 52 Week High
  • ACET $1.19
  • BW $7.77
  • Technical
  • Relative Strength Index (RSI)
  • ACET 36.18
  • BW 62.95
  • Support Level
  • ACET $0.57
  • BW $5.35
  • Resistance Level
  • ACET $0.67
  • BW $6.21
  • Average True Range (ATR)
  • ACET 0.06
  • BW 0.80
  • MACD
  • ACET 0.00
  • BW -0.10
  • Stochastic Oscillator
  • ACET 26.97
  • BW 51.12

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: